Document:

DMBM INC

16 Ann Marie Drive

Saint James, New York 11780

As of December 13, 2012

VG Life Sciences Inc

2290 Huntington Drive, Suite 100

San Marino, CA 91108

Attn:. Mr. Haig Keledj ian

 

President

 

Dear Mr. Keledjian:

 

This letter
agreement (this "Agreement’) shall confirm the understanding and agreement between DMBM Inc (the "Lender"),
and VG Lite Sciences, Inc (the "Company"), with respect to the Loan (as hereinafter defined) from the Lender to the Company.

 

That understanding and agreement in as follows:

 

1.The
Lender will loan $20,000 to VG Life Sciences. The Company has advised DMBM, that the Company does not have sufficient cash to pay
amounts owing to ifs transfer agent and it is necessary to pay the transfer agent now to maintain a market in the Company's common
stock.:

2.The
proceeds of the Loan shall only be used to pay the Company transfer agent.

 

3.The
Loan will be evidenced by a convertible promissory note made by the Company (the "Note"), shall mature and be payable
six (6) months after the date of issuance (the "Maturity Date") and shall earn interest on the outstanding principal
amount of the Note at a rate of 2% per annum (calculated on the basis of a year of 360 days). The Note shall not be prepayable.

 

4.The
Note, shall be convertible prior to the Maturity Date, at the sole option of the Lender, upon two (2) business days prior written
notice to the Company, into shares of the Company's common stock at a conversion price of $0.15 per share (the "Conversion
Price.). Notwithstanding, anything set forth in the immediately preceding sentence, the Conversion Price shall be lowered
to the lowest price per share at which the Company issues common stock (including, without limitation, by means of the conversion
of any security of the issuance of shares under any warrant) as long as this Note is outstanding. The Conversion Price shall be
subject to customary anti-dilution protection.

 

5.In
consideration of making the Loan, the Company shall lower the conversion price on $30,000 of the principal amount of the convertible
debenture dated November 25, 2011 issued by the company to DMBM to $.00025 Per Share.($.15 Per share post 600 to 1 reverse split)

 

6.Each party hereby represents and warrants
to the other parties that:

 

(a) it has the full power, ability, legal capacity
and authority to execute and deliver the Agreement and to perform its obligations hereunder; and

 

    	1

    	 

    

 

(b) this Agreement constitutes its legal,
valid and biding obligation, enforceable against it in accordance with its term, except as enforceability may be limited by applicable
bankruptcy, moratorium, insolvency and other similar laws affecting the enforcement of creditors" rights generally and that
enforcement may be limited by general principles of equity.

 

7.This Agreement may not be amended, modified,
waived or terminate, except by an instrument in writing executed by each of the parties hereto. Any waiver of any provision of
this Agreement shall be limited to the specific instance and purpose for which it is given.

 

8.This Agreement shall not be assigned
by any party without the prior written consent of the other party and their respective successors and permitted assignees,

 

9.This Agreement shall be governed by and
construed in accordance with the laws of the State of New York, without regard to any of its conflicts of law principles which
would result in the application of the laws of another jurisdiction.

 

10.The Agreement may be executed in counterparts
(and they may be executed by facsimile or electric signature which shall be valid for purposes hereof) each of which shall be an
original, and all of which, when taken together, shall constitute over and the same agreement. In resolving nay dispute or controversy
arising out of this Agreement or construing any term or provision in this Agreement, there shall be no presumption made or inference
drawn because of the inclusion of a provision not contained, in a prior draft or deletion of a provision contained in a prior draft
this Agreement shall not be construed or interpreted with any presumption against either party and for purposes of construing and
interpreting, this Agreement, it shall be deemed that this Agreement was drafted jointly by the parties. Any reference in this
Agreement to the masculine, feminine or neuter gender shall be a reference to such other gender as if appropriate. References in
this Agreement to the singular shall include the plural and vice versa.

 

Please confirm the Company agreement to this
Agreement by executing and returning the enclosed copy of this Agreement to the Lender.

 

 

	 	Very Truly yours,

DMBM - Lender

By: /s/ Damon Roberts

Name:

Title: President

 

 

Agreed and Accepted:

 

VG LIFE SCIENCES, INC.

 

By: /s/ Haig Keledjian

Name: Haig Keledgian

Title: PresidentExhibit 10.100

 

DMBM
INC

16 Ann Marie Drive

Saint James, New York 11780

As of December 13, 2012

VG Life Sciences Inc.

2290 Huntington Drive, Suite 100

San Marino, CA 91108

Attn: Mr. Haig Keledjian

President

Dear
Mr. Keledjian:

This
letter agreement (this "Agreement") shall confirm the understanding and agreement between DMBM Inc. (the "Lender"),
and VG Life Sciences. Inc., (the "Company"), with respect to the Loan (as hereinafter defined) from the Lender to the
Company.

That understanding and agreement in as follows:

1.     
The Lender will loan $20,000 to VG Life Sciences. The Company has advised DMBM, that the Company does not have sufficient
cash to pay amounts owing to it's transfer agent and it is necessary to pay the transfer agent now to maintain a market in the
Company's common stock.

2.     
The proceeds of the Loan shall only be used to pay the Company transfer agent.

3.     
The Loan will be evidenced by a convertible promissory note made by the Company (the 'Note"), shall mature and be payable
six (6) months after the date of issuance (the "Maturity Date") and shall earn interest on the outstanding principal
amount of the Note at a rate of 2% per annum (calculated on the basis of a year of 360 days). The Note shall not be prepayable.

4.     
The Note, shall be convertible prior to the Maturity Date, at the sole option of the Lender, upon two (2) business days
prior written notice to the Company, into shares of the Company's common stock at a conversion price of $0.15 per share (the "Conversion.
Price"). Notwithstanding anything set forth in the immediately preceding sentence, the Conversion Price shall be lowered to
the lowest price per share at which the Company issues common stock (including, without limitation, by means of the conversion
of any security of the issuance of shares under any warrant) as long as this Note is outstanding. The Conversion Price shall be
subject to customary anti-dilution protection.

5.     
Each party hereby represents and warrants to the other parties that:

(a)   
it has the full power, ability, legal capacity and authority to execute and deliver the Agreement and to perform its obligations
hereunder; and

(b)  
this Agreement constitutes its legal. valid and biding obligation, enforceable against it in accordance with its term,
except as enforceability may be limited by applicable bankruptcy, moratorium, insolvency and other similar laws affecting the
enforcement of creditors' rights, generally and that enforcement may be limited by general principles of equity.

    	1

    	 

    

6.     
This Agreement may not be amended, modified, waived or terminate, except by art instrument m writing executed by each of
the parties hereto. Any waiver of any provision of this Agreement shall be limited to the specific instance and purpose for which
it is given.

7.     
This Agreement shall not be assigned by any party without the prior written consent of --the other party and
their respective successors and permitted assignees,

8.     
This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to
any of its conflicts of law principles which would result in the application of the laws of another jurisdiction.

9.     
The Agreement may be executed in counterparts (and they may be executed by facsimile or electric signature which shall be
valid for purposes hereof) each of which shall be an original, and all of which, when taken together, shall constitute over and
the same agreement. In resolving nay dispute or controversy arising out of this Agreement or construing any term or provision in
this Agreement, there shall be no presumption made or inference drawn because of the inclusion of a provision not contained in
a prior draft or deletion of a provision contained in a prior draft This Agreement shall not be construed or interpreted with any
presumption against either party and for purposes of construing and interpreting this Agreement, it shall be deemed that this Agreement
was drafted jointly by the parties. Any reference in this Agreement to the masculine, feminine or neuter gender shall be a reference
to such other gender as if appropriate, References in this Agreement to the singular shall include the plural and vice versa.

Please
confirm the Company agreement to this Agreement by executing and returning the enclosed copy of this Agreement to the Lender.

 

 

    	2Exhibit 10.101

 

 

THE SECURITIES REPRESENTED
BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH
A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE
REGISTRATION STATEMENT UNLESS AN EXEMPTION FROM REGISTRATION IS AVAILABLE UNDER THE SECURITIES ACT OF 1933 (THE "SECURITIES
ACT").

 

RESTATED CONVERTIBLE
DEBENTURE

 

	$64,000.00	As of December 23, 2011

 

For value received,
Viral Genetics, Inc., a Delaware corporation (the "Company"), promises to pay to the order of DMBM Inc. (the "Holder"),
the principal sum of SIXTY FOUR THOUSAND DOLLARS AND NO CENTS or the aggregate outstanding principal amount hereof, whichever
is less (the "Principal"), represents various loans (each a "Loan") made by the Holder to the Company between
December 1, 2011 and December 23, 2011, on the dates and in the amounts specified on Schedule A attached hereto and to pay interest
on the outstanding principal amount of this Convertible Debenture (this "Debenture") as provided herein.

 

1.
Definitions. The following terms shall have the
definitions set forth in this Section 1:

 

(a)
"Business Day" means any day on which banks are open for business in both the State of California and the State of New
York.

 

(b)
"Common Stock" means the Company's common stock, par value $0.0001 per Share.

 

(c) "Conversion Price" shall
be $0.00075 per Share.

 

(d)
"Shares" means shares of Common Stock.

 

(e)
"Trading Day" means a calendar day on which the Shares are quoted for trading on the Trading Market.

 

(f)
"Trading Market" means the following markets or exchanges on which the Shares are listed or quoted for trading on the
date in question: The Over The Counter Bulletin Board, the PinkSheets, the Nasdaq SmallCap Market, the American Stock Exchange,
the New York Stock Exchange, the Nasdaq National Market, the Toronto Stock Exchange, the TSX Venture Exchange, or any other securities
exchange registered with the United States Securities and Exchange Commission.

 

2.
Loans. Each Loan made by the Holder to the Company evidenced by this Debenture, shall be set forth on Schedule A attached
hereto. The Holder is authorized by the Company to modify Schedule A from time to time to reflect the amount of any partial conversion
of this Debenture.

 

    	1

    	 

    

 

 

3.
Interest. Interest on the outstanding Principal amount of this Debenture will accrue at a rate equal to one percent (1%) per
annum from the date of the making of each Loan as set forth on Schedule A. Interest will be computed on the basis of a year of
12 months, each having 30 days, and will be paid on the Maturity Date and upon any permitted prepayment of this Debenture.

 

4.
Repayment. The Company shall pay the Principal amount of this Debenture, together with all accrued and unpaid interest, to
the Holder on May 31, 2013 (the "Maturity Date").

 

5.
Payment. All payments due under this Debenture shall be made in either the lawful money of the United States of America or
in Shares, as determined by the Company in its discretion in accordance with Section 5 hereof, without set-off, deduction, demand
or notice.

 

		(a)	Form of Payment. Five (5) business days prior to
the Maturity Date, the Company, at its sole discretion, shall notify the Holder whether the payment due on the Maturity Date shall
be made in cash or in Shares.

 

		(b)	Payment in Cash. All payments in cash shall be made
to the Holder by check or by wire transfer to such bank as the Holder may advise the Company in writing.

 

		(c)	Payment in Shares. The number of Shares issuable
upon a payment being made in Shares shall be calculated by dividing the aggregate amount due on the Maturity Date by the Conversion
Price. No fractional Shares will be issued upon conversion of this Debenture or a payment by the Company in Shares. In lieu of
any fractional Share to which the Holder would otherwise be entitled upon a payment in Shares, the Company will pay to the Holder
in cash the amount of the unpaid or unconverted Principal and interest balance of this Debenture that would otherwise be paid
or converted into such fractional Share. Shares issued hereunder shall be transmitted by the transfer agent of the Company to
the Holder either by crediting the account of the Holder's designated broker with the Depository Trust Company through its Deposit
Withdrawal Agent Commission ("DWAC"), or, if so elected by Holder, by physical delivery of certificates to Holder's
address within five (5) Trading Days from the Due Date. If the Company fails for any reason to deliver to the Holder the Shares
by the requisite delivery date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for
each $1,000 of Shares not timely delivered, $5 per Trading Day (increasing to $10 per Trading Day on the fifteenth (15) Trading
Day after such liquidated damages begin to accrue) for each Trading Day after such requisite delivery date until such Shares are
delivered. In addition to any other rights available to the Holder, if the Company fails to cause its transfer agent to deliver
to the Holder the Shares on or before the requisite delivery date, and if after such date the Holder is required by its broker
to purchase (in an open market transaction or otherwise), or the Holder's brokerage firm otherwise purchases, Shares to deliver
in satisfaction of a sale by the Holder of the Shares which the Holder anticipated receiving pursuant to this Debenture (a "Buy-In"),
then the Company shall (1) pay in cash to the Holder the amount by which (x) the Holder's total purchase
price (including brokerage commissions, if any) for the Shares so purchased exceeds (y) the amount obtained by multiplying (A)
the number of Shares that the Company was required to deliver to the Holder multiplied by (B) the price at which the sell order
giving rise to such purchase obligation was executed, and (2) deliver to the Holder the number of Shares that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases
Shares having a total purchase price of $11,000 to cover a Buy-In with an aggregate sale price giving rise to such purchase obligation
of $10,000, under clause (1) of the immediately preceding sentence the Company shall be required to pay the Holder $ 1,000. The
Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon
request of the Company, commercially reasonable evidence of the amount of such loss.

 

 

    	2

    	 

    

 

		(d)	Adjustments.
If the Company, at any time while this Debenture is outstanding subdivides outstanding Shares into a larger number of shares
or combines (including by way of reverse stock split) outstanding Shares into a smaller number of shares, then the Conversion
Price shall be multiplied by a fraction of which the numerator shall be the number of Shares outstanding immediately before such
event and of which the denominator shall be the number of Shares outstanding immediately after such event.

 

6.
Prepayment. This Debenture may not be prepaid by the Company without the prior written consent ofthe Holder, except as provided
in Section 7 of this Debenture .

 

7.
Conversion. At any time prior to five (5) business days prior to the Maturity Date, all or
any portion of the Principal amount of this Debenture, together will accrued interest thereon, may be converted at the option
of the Holder, at any time and from time to time, in the minimum principal amount of $5,000 and integral multiples of $1,000 thereafter,
upon not less than two (2) three (3) Business Days after the Company's receipt of the Conversion Notice (as hereinafter defined)
from the Holder and payment in full of the Conversion Price as then in effect. Each "Conversion Notice" shall mean a
written notice from the Holder informing the Company of the date of the conversion, the principal amount of this Debenture being
converted, the number of shares of Common Stock to be received upon conversion and confirming that the Conversion Price will be
paid in cash. The Conversion Price shall be paid by certified check or by wire transfer of immediately available funds to a bank
account designated by the Company in writing. Within three (3) Business Days after payment of the Conversion Price, the Company
will deliver a certificate for the shares of Common Stock issued upon conversion to the Holder, or at the Holder's request, to
a brokerage account for the benefit of Holder. The Company shall at all times reserve for issuance a number of shares of Common
Stock sufficient to satisfy the conversion feature of this Debenture. The number of shares of Common Stock issuable upon the conversion
of all or a portion of this Debenture shall be equal to the Principal amount of this Debenture being converted divided by the
Conversion Price. For purposes hereof, any partial conversion of this Debenture, each Loan shall be considered separate and distinct
indebtedness of the Company to the Holder for purposes of determining the holding period of each item of indebtedness represented
by the Loan. Notwithstanding anything set forth herein, in no event shall the Holder be entitled to convert this Debenture for
a number of shares of Common Stock in excess of that number of shares of Common Stock which, upon giving effect to such conversion,
would cause the aggregate number of shares of Common Stock beneficially owned by the Holder and its affiliates to exceed 9.99%
of the outstanding shares of the Common Stock following such conversion. Notwithstanding receipt of a Conversion Notice, the Company
shall have the right to prepay this Debenture in the amount being converted if the principal amount to be converted together with
accrued interest thereon is paid in immediately available funds within one (1) business day after the date of the

 

    	3

    	 

    

 

 

8.
Seniority. The indebtedness represented by this Debenture is and shall be an obligation of the Company ranking senior in right
of payment, liquidation and otherwise to any future indebtedness and other obligations of the Company. The Company will not create
any indebtedness that is senior in priority to the indebtedness represented by this Debenture.

 

9.
Default. Any one of the following occurrences shall constitute an "Event of Default" under this Debenture:

 

(a)
failure of Company to pay any amount that it payable under this Debenture on the Due Date, provided that such failure is not cured
within a grace period of ten (10) calendar days; or

 

(b)
failure to comply with or perform any other agreement or covenant of the Company contained herein, which failure does not otherwise
constitute an Event of Default, provided that such failure has not been cured within thirty (30) calendar days written notice
by Holder to the Company; or

 

(c)
there shall occur any default or event of default, any similar event, any event that requires the prepayment of borrowed money
or permits the acceleration of the maturity thereof, or any event or condition that might become any of the foregoing with notice
or the passage of time or both, under the terms of any evidence of indebtedness or other agreement issued or assumed or entered
into by the Company, or under the terms of any document or instrument under which any such evidence of indebtedness or other agreement
is issued, assumed, secured, or guaranteed, and such event shall continue beyond any applicable notice, grace or cure period,
provided that such condition shall not have been cured within thirty (30) calendar days of notice by Holder; or

 

(d)
the Company shall fail to maintain its existence in good standing in its state of incorporation; provided that such condition
shall not have been cured within thirty (30) calendar days of notice by Holder; or

 

(e)
a judgment or settlement shall be entered or agreed to in any proceeding which would reasonably be expected to have a material
and adverse effect on the ability of the Company to repay this Debenture; or any garnishment, summons, writ of attachment, citation,
levy or the like is issued against or served upon Holder for the attachment of any property of the Company in Holder's possession
or control, provided that such condition shall not have been cured within thirty (30) calendar days of notice by Holder of such
condition; or

 

    	4

    	 

    

 

 

(f)
any Share issued pursuant to this Debenture shall not be duly authorized, validly issued, fully paid or nonassessable, provided
that such condition shall not have been cured within ninety (90) calendar days of notice by Holder of such condition; or

 

(g)
the Company shake make a voluntary filing for bankruptcy under Title 11, Chapter 7 of the United States Code; or

 

(h) there shall
be appointed a receiver or trustee to take possession of the property or assets of the Company under Title 11, Chapter 7 of the
United States Code.

 

10.
Remedies. Upon the occurrence and during the continuance
of an Event of Default, this Debenture and shall become immediately due in full, and unpaid amounts hereunder will accrue interest
at the rate equal to the stated rate plus 5.00% per annum, and Holder may exercise any rights and remedies under this Debenture,
any Transaction Document or other document or instrument and at law or in equity. The time of payment of this Debenture is also
subject to acceleration if an Event of Default occurs. Notwithstanding the foregoing, the entire unpaid Principal sum of this
Debenture, together with accrued and unpaid interest thereon, shall become immediately due and payable upon any of the Events
of Default set forth in this Debenture.

 

11.
Transfer; Successors and Assigns. The terms and
conditions of this Debenture shall inure to the benefit of and be binding upon the respective successors and assigns of the parties.
At the election of the Holder, but subject-to compliance with applicable securities laws, this Debenture may be assigned or transferred
by the Holder, in whole or in part, upon surrender of this Debenture, duly endorsed, and accompanied by a duly executed written
instrument of transfer in customary form, following which a new Debenture for the same principal amount and interest will be issued
to, and registered in the name of, the transferee. If less than the entire amount of this Debenture is transferred or assigned,
the Company will issue new Debentures to the transferee, in the amount transferred or assigned, and to the Holder, in the remaining
Principal amount hereof after the transfer or assignment. This Debenture shall be binding upon and inure to the benefit of the
Company and the Holder, their successors and permitted assigns and the transferees of the Holder.

 

12.
Governing Law. This Debenture and all acts and transactions
pursuant hereto and the rights and obligations of the Company and the Holder shall be governed, construed and interpreted in accordance
with the laws of the State of New York, without giving effect to any of its principles of conflicts of law or choice of law principles
which would result in the application of the laws of another jurisdiction.

 

13.
Notices. Any notice required or permitted by this
Debenture shall be in writing and shall be deemed sufficient upon receipt, when delivered personally or by courier, overnight
delivery service or confirmed facsimile, or 96 hours after being deposited in the U.S. mail as certified or registered mail with
postage prepaid, if such notice is addressed to the party to be notified at such party's address or facsimile number as set forth
herein or as subsequently modified by written notice.

 

    	5

    	 

    

 

14.
Amendments and Waivers. This Debenture may only be amended, modified or waived by a written instrument executed by the Company
and the Holder. Any amendment or waiver effected in accordance with this Section 14 shall be binding upon the Company, the Holder
and each transferee or permitted assigns of any Debenture.

 

15.
Loss of Debenture. Upon receipt by the Company of a customary representation by the Holder of the loss, theft, destruction
or mutilation of this Debenture or any Debenture exchanged for it, and a customary indemnity undertaking by the Holder (in case
of loss, theft or destruction) or surrender and cancellation of such Debenture {in the case of mutilation), the Company will make
and deliver in lieu of such Debenture a new Debenture of like tenor.

 

16.
Waiver of Presentment, etc. The Company hereby expressly waives presentment, demand for payment, dishonor, notice of dishonor,
protest, notice of protest and any other formality upon the occurrence of an Event of Default.

 

17.
Entire Understanding. This Debenture sets forth the entire understanding agreement of the Company and the Holder with respect
to the subject matter hereof and it supersedes all prior and/or contemporaneous understandings and agreements with respect to
such subject matter, all of which are merged herein, and it specifically amends and restates a Debenture dated this date in the
same principal amount hereof, which did not accurately reflect the understanding and agreement of the Company and the Holder.

 

18.
Costs and Fees. The Company agrees to pay all costs, expenses, including, without limitation, reasonable attorneys' fees and
disbursements, incurred by the Holder in endeavoring to collect any amounts payable hereunder (including, without limitation,
amounts payable in Shares) which are not paid when due or otherwise in enforcing any provision of this Debenture and any of the
rights and remedies of the Holder under this Debenture, at law or in equity.

 

[signature page follows]

 

    	6

    	 

    

 

IN WITNESS WHEREOF, this
Debenture has been executed by a duly authorized officer of the Company as of the date first written above.

 

 

COMPANY

 

VIRAL
GENETICS, INC.

 

 

By:
/s/ Haig Keledjian                   

Name:
Haig Keledjian

Title: President

 

 

    	7

    	 

    

 

Schedule A

 

	
        Date of Loan
	
        Amount
        of Loan
	
	 	 	 
	
        12/23/11
	
        WIRE TRANSFER OUTGOING Viral Genetics Inc
	
        $14,000.00

	 	 	 
	
        12/20/11
	
        WIRE TRANSFER OUTGOING Viral Genetics Inc
	
        $5,000.00

	 	 	 
	
        12/18/11
	
        WIRE TRANSFER OUTGOING Viral Genetics Inc
	
        $5,000.00

	 	 	 
	
        12/16/11
	
        WIRE TRANSFER OUTGOING Viral Genetics Inc
	
        $10,000.00

	 	 	 
	
        12/12/11
	
        WIRE TRANSFER OUTGOING Viral Genetics Inc
	
        $10,000.00

	 	 	 
	
        12/08/11
	
        WIRE TRANSFER OUTGOING Viral Genetics Inc
	
        $5,000.00

	 	 	 
	
        12/06/11
	
        WIRE TRANSFER OUTGOING Viral Genetics Inc
	
        $5,000.00

	 	 	 
	
        12/05/11
	
        WIRE TRANSFER OUTGOING Viral Genetics Inc
	
        $5,000.00

	 	 	 
	
        12/02/11
	
        WIRE TRANSFER OUTGOING Viral Genetics Inc
	
        $5,000.00

 

 

    	8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]